Business
Receives TSB Grant for Bio-imaging
Receives TSB Grant for Bio-imaging.
About this update from Nanoco Group Plc
[{"type":"text","content":"\n \nRNS Number : 1627J Nanoco Group PLC 09 June 2014 \n \n\n\n\n\n\nFor immediate release \n\n\n9 June 2014\n\n\n\n\n \n \nNANOCO GROUP PLC\n(\"Nanoco\" or \"the Company\")\n \nReceives Technology Strategy Board Grant for Bio-imaging\n \nNanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it has been awarded a further £308,000 grant to support its research at University College London (UCL) into the use of cadmium-free quantum dots in the in-vivo imaging of cancer. \n \nThe grant has been awarded by the Technology Strategy Board (TSB), the UK's innovation agency, under its Biomedical Catalyst funding programme. UCL will also receive a TSB grant under the Biomedical Catalyst programme to support the project.\n \nNanoco and UCL began joint research work in 2011 in which the fluorescence of Nanoco quantum dots is being used to pinpoint malignant lymph nodes to guide surgeons in the removal of cancerous tissue. Other materials have already been used in this way in clinical practice but Nanoco quantum dots offer the major advantage of fluorescing for a longer period of time, giving surgeons a greater opportunity to remove cancer cells.\n \nThe TSB funding announced today will be used to support the next stage of the joint research programme.\n \n \nMichael Edelman, Nanoco's Chief Executive Officer, said: \"We're delighted to receive this grant award from the Technology Strategy Board for our exciting work with University College London in cancer imaging. Our work to date shows that the sustained fluorescence achievable with Nanoco quantum dots has the potential to give surgeons a much greater window than currently available for the removal of cancer cells. \n \n\"We look forward to continuing this research with the ultimate objective of our technology becoming part of a commercially available bio-imaging product. This bio-imaging research highlights the versatility of our core cadmium-free quantum dot technology and its multiple potential commercial applications of which the display sector is our lead focus.\"\n \nFor further information please contact:\n\n\n\n\nNanoco\n\n\n+ 44 (0) 161 603 7900\n\n\n\n\nMichael Edelman, Chief Executive Officer\n\n\n\n\n\n\n\nColin White, Chief...